Drug Profile
Valiltramiprosate - Alzheon
Alternative Names: ALZ 801; BLU-8499; NRM-8499; Tramiprosate prodrug - AlzheonLatest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator BELLUS Health
- Developer Alzheon; BELLUS Health; National Institute on Aging
- Class Alkanesulfonic acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
- Phase II Cerebral amyloid angiopathy; Down syndrome
Most Recent Events
- 08 Apr 2024 The United States Federal Circuit Affirms decision of US Patent Office to invalidate Risen Pharmaceutical’s patent on isotopically enriched forms of valiltramiprosate
- 26 Mar 2024 Alzheon completes enrollment in the phase III APOLLOE4 trial in Alzheimer's disease (Early-stage disease) in Netherlands, Czech Republic, United Kingdom, Spain, Iceland, France, Germany, Canada and USA (PO) (NCT04770220) (EudraCT2020-005755-20)
- 13 Sep 2023 Adverse events and pharmacodynamics data from a phase II trial in Alzheimer's disease released by Alzheon